ICON PLC
ICLR Healthcare Diagnostics & Research
ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024.
- Revenue
- −2.86%
- EPS
- +143.2%
- Free cash flow
- −8.01%
- Total debt
- −0.86%
Quarter to September 2026, against a year earlier
Follow ICLR
Alert me
ICON PLC (ICLR) P/E ratio
As of 5 November 2026, ICON PLC (ICLR) trades at a P/E ratio of 34.5×. Over the past ten years it has ranged from 14.7× (May 2016) to 307× (July 2026); the current reading is higher than 67% of that period. That is in line with the Diagnostics & Research industry median of 34.5× and above the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 66.1× | 182.55% |
| FY2024 | 23.4× | (37.86%) |
| FY2023 | 37.6× | 20.36% |
| FY2022 | 31.3× | (69.60%) |
| FY2021 | 103× | 227.17% |
| FY2020 | 31.4× | 25.08% |
| FY2019 | 25.1× | 15.98% |
| FY2018 | 21.7× | (1.72%) |
| FY2017 | 22.1× | 42.01% |
| FY2016 | 15.5× | (18.24%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 29.1× | (90.17%) |
| Jun 2026 | 296× | 492.72% |
| Mar 2026 | 49.9× | (24.48%) |
| Dec 2025 | 66.1× | 26.24% |
| 43 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GH Guardant Health, Inc. compare | n/m |
| DGX Quest Diagnostics Incorporated compare | 25.0× |
| QGEN QIAGEN N.V. compare | 26.1× |
| LH Labcorp Holdings Inc. compare | 29.5× |
| ICLR ICON PLC | 34.5× |
| MEDP Medpace Holdings, Inc. compare | 34.6× |
| ILMN Illumina, Inc. compare | 35.6× |
| RVTY Revvity Inc. compare | 71.9× |
| CRL Charles River Laboratories International, Inc. compare | 300× |
| Diagnostics & Research industry median | 34.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on ICLR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement